On the public citation graph

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis

https://doi.org/10.1371/journal.pone.0043090
0 signed · 151 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 36 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1074/jbc.m109.065862 (notice 2015-03-06).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/gcc.20748openalex-snapshot
Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis
inferredcites →https://doi.org/10.1016/j.ccr.2010.11.015openalex-snapshot
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
inferredcites →https://doi.org/10.1016/s0145-2126(01)00021-2openalex-snapshot
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings
inferredcites →https://doi.org/10.1016/s0145-2126(01)00038-8openalex-snapshot
Diagnostic criteria and classification of mastocytosis: a consensus proposal
inferredcites →https://doi.org/10.1016/s0145-2126(02)00303-xopenalex-snapshot
Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease
inferredcites →https://doi.org/10.1016/s0301-472x(99)00145-9openalex-snapshot
Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
inferredcites →https://doi.org/10.1016/s1040-1741(10)79468-9openalex-snapshot
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
inferredcites →https://doi.org/10.1038/leu.2009.37openalex-snapshot
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
inferredcites →https://doi.org/10.1038/leu.2010.144openalex-snapshot
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration
inferredcites →https://doi.org/10.1038/leu.2010.167openalex-snapshot
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies
inferredcites →https://doi.org/10.1038/leu.2010.69openalex-snapshot
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
inferredcites →https://doi.org/10.1038/leu.2011.44openalex-snapshot
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
inferredcites →https://doi.org/10.1038/nature08617openalex-snapshot
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
inferredcites →https://doi.org/10.1038/nature09132openalex-snapshot
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
inferredcites →https://doi.org/10.1038/ng.268openalex-snapshot
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation
inferredcites →https://doi.org/10.1038/sj.leu.2404757openalex-snapshot
Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes
inferredcites →https://doi.org/10.1038/sj.onc.1206120openalex-snapshot
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms
inferredcites →https://doi.org/10.1056/nejmc0910063openalex-snapshot
Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
inferredcites →https://doi.org/10.1056/nejmoa1005143openalex-snapshot
DNMT3A Mutations in Acute Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1013343openalex-snapshot
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
inferredcites →https://doi.org/10.1073/pnas.92.23.10560openalex-snapshot
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
inferredcites →https://doi.org/10.1074/jbc.m109.065862openalex-snapshot
ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
inferredcites →https://doi.org/10.1084/jem.20092506openalex-snapshot
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
inferredcites →https://doi.org/10.1097/00062752-200401000-00009openalex-snapshot
Clinical, genetic, and therapeutic insights into systemic mast cell disease
inferredcites →https://doi.org/10.1111/j.0960-135x.2004.01369.xopenalex-snapshot
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts
inferredcites →https://doi.org/10.1111/j.1365-2141.2010.08196.xopenalex-snapshot
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations
inferredcites →https://doi.org/10.1111/j.1365-2141.2010.08381.xopenalex-snapshot
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
inferredcites →https://doi.org/10.1111/j.1365-2362.2007.01807.xopenalex-snapshot
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria
inferredcites →https://doi.org/10.1182/blood-2002-01-0203openalex-snapshot
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene
inferredcites →https://doi.org/10.1182/blood-2006-04-015545openalex-snapshot
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
inferredcites →https://doi.org/10.1182/blood-2007-05-092304openalex-snapshot
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
inferredcites →https://doi.org/10.1182/blood-2009-02-205690openalex-snapshot
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
inferredcites →https://doi.org/10.1182/blood-2010-10-311019openalex-snapshot
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
inferredcites →https://doi.org/10.1182/blood.v118.21.sci-31.sci-31openalex-snapshot
DNMT3A Mutations in Acute Myeloid Leukemia
inferredcites →https://doi.org/10.1182/blood.v94.7.2333.419k30_2333_2342openalex-snapshot
Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13)
inferredcites →https://doi.org/10.1200/jco.2009.23.7503openalex-snapshot
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3942586openalex-extracted
Loss Of Tet2 In T Cells Drives Translocated Pathobiont Derived Aryl Hydrocarbon Receptor Agonist-Induced Tc1 Cell Autoimmune Hepatitis
inferred← citeshttps://doi.org/10.1002/9781118527948.ch2openalex-snapshot
Molecular genetics of the myeloproliferative neoplasms
inferred← citeshttps://doi.org/10.1002/acg2.78openalex-snapshot
Update on the classification of myeloid neoplasms: The 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms
inferred← citeshttps://doi.org/10.1002/clt2.12074openalex-snapshot
DNA methylation profile in patients with indolent systemic mastocytosis
inferred← citeshttps://doi.org/10.1002/gcc.22342openalex-snapshot
Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray‐based whole‐genome scanning
inferred← citeshttps://doi.org/10.1002/pbc.29012openalex-snapshot
Successful treatment of acute myeloid leukemia and mast cell proliferation in a patient with autoimmune lymphoproliferative syndrome
inferred← citeshttps://doi.org/10.1002/vms3.201openalex-snapshot
Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment
inferred← citeshttps://doi.org/10.1002/vms3.66openalex-snapshot
Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours
inferred← citeshttps://doi.org/10.1007/978-3-030-22922-1_15openalex-snapshot
Chronic Myeloid Neoplasms
inferred← citeshttps://doi.org/10.1007/978-3-030-27820-5_13openalex-snapshot
KIT and Other Mutations in Mastocytosis
inferred← citeshttps://doi.org/10.1007/978-3-030-27820-5_14openalex-snapshot
Management of Hematologic Disease in Mastocytosis
inferred← citeshttps://doi.org/10.1007/978-3-030-73227-1_14openalex-snapshot
Myeloproliferative Neoplasms, Myelodysplastic/Myeloproliferative Neoplasms, and Myelodysplastic Syndromes
inferred← citeshttps://doi.org/10.1007/978-3-319-26587-2_83-1openalex-snapshot
Systemic Mastocytosis and Mast Cell Tumors
inferred← citeshttps://doi.org/10.1007/978-3-319-26956-6_83openalex-snapshot
Systemic Mastocytosis and Mast Cell Tumors
inferred← citeshttps://doi.org/10.1007/s00251-017-0981-yopenalex-snapshot
Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing
inferred← citeshttps://doi.org/10.1007/s00277-013-1964-1openalex-snapshot
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
inferred← citeshttps://doi.org/10.1007/s10238-021-00693-0openalex-snapshot
Vascular endothelial growth factors and angiopoietins as new players in mastocytosis
inferred← citeshttps://doi.org/10.1007/s11899-018-0469-3openalex-snapshot
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
inferred← citeshttps://doi.org/10.1007/s12185-023-03586-yopenalex-snapshot
Epigenetic regulation by ASXL1 in myeloid malignancies
inferred← citeshttps://doi.org/10.1016/j.banm.2024.03.009openalex-snapshot
Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations
inferred← citeshttps://doi.org/10.1016/j.cell.2013.11.020openalex-snapshot
Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation
inferred← citeshttps://doi.org/10.1016/j.celrep.2014.10.039openalex-snapshot
Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis
inferred← citeshttps://doi.org/10.1016/j.chom.2022.05.006openalex-snapshot
Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2014.09.001openalex-snapshot
The genetic basis of mast cell activation disease - looking through a glass darkly
inferred← citeshttps://doi.org/10.1016/j.iac.2014.01.009openalex-snapshot
Molecular Defects in Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.iac.2014.01.012openalex-snapshot
Treatment Strategies in Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.iac.2018.04.005openalex-snapshot
Kit Mutations
inferred← citeshttps://doi.org/10.1016/j.iac.2018.04.007openalex-snapshot
Tyrosine Kinase Inhibition in Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.iac.2023.04.008openalex-snapshot
KIT Mutations and Other Genetic Defects in Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.iac.2023.04.009openalex-snapshot
Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms
inferred← citeshttps://doi.org/10.1016/j.iac.2023.04.011openalex-snapshot
World Health Organization Classification and Diagnosis of Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.jaci.2022.04.004openalex-snapshot
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
inferred← citeshttps://doi.org/10.1016/j.jaip.2022.03.001openalex-snapshot
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
inferred← citeshttps://doi.org/10.1016/j.jaip.2025.07.055openalex-snapshot
Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis
inferred← citeshttps://doi.org/10.1016/j.jmoldx.2018.07.002openalex-snapshot
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
inferred← citeshttps://doi.org/10.1016/j.leukres.2014.07.010openalex-snapshot
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412
inferred← citeshttps://doi.org/10.1016/j.lrr.2023.100409openalex-snapshot
Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation
inferred← citeshttps://doi.org/10.1016/j.reval.2013.12.004openalex-snapshot
Anomalies moléculaires au cours des mastocytoses : conséquences pronostiques et thérapeutiques
inferred← citeshttps://doi.org/10.1016/j.trsl.2016.01.001openalex-snapshot
Transgenerational transmission of systemic mast cell activation disease—genetic and epigenetic features
inferred← citeshttps://doi.org/10.1038/leu.2015.284openalex-snapshot
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.1038/leu.2015.4openalex-snapshot
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
inferred← citeshttps://doi.org/10.1038/ncomms8307openalex-snapshot
Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
inferred← citeshttps://doi.org/10.1038/nrc3895openalex-snapshot
DNMT3A in haematological malignancies
inferred← citeshttps://doi.org/10.1038/s41375-019-0450-8openalex-snapshot
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.1038/s41392-024-02050-5openalex-snapshot
Tissue-resident immune cells: from defining characteristics to roles in diseases
inferred← citeshttps://doi.org/10.1038/s41577-022-00731-2openalex-snapshot
New perspectives on the origins and heterogeneity of mast cells
inferred← citeshttps://doi.org/10.1053/j.seminhematol.2018.05.005openalex-snapshot
Advances in diagnosis of mastocytosis and hypereosinophilic syndrome☆
inferred← citeshttps://doi.org/10.1073/pnas.1616420114openalex-snapshot
Dnmt3a restrains mast cell inflammatory responses
inferred← citeshttps://doi.org/10.1080/10428194.2019.1703974openalex-snapshot
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019
inferred← citeshttps://doi.org/10.1080/10428194.2024.2410942openalex-snapshot
Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation
inferred← citeshttps://doi.org/10.1080/10428194.2025.2604560openalex-snapshot
Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy
inferred← citeshttps://doi.org/10.1080/17512433.2017.1387051openalex-snapshot
Midostaurin treatment inFLT3-mutated acute myeloid leukemia and systemic mastocytosis
inferred← citeshttps://doi.org/10.1084/jem.20170910openalex-snapshot
The transcriptional program, functional heterogeneity, and clinical targeting of mast cells
inferred← citeshttps://doi.org/10.1093/annonc/mdx290openalex-snapshot
Midostaurin: a magic bullet that blocks mast cell expansion and activation
inferred← citeshttps://doi.org/10.1097/hs9.0000000000000646openalex-snapshot
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
inferred← citeshttps://doi.org/10.1097/md.0000000000028651openalex-snapshot
A case of systemic mastocytosis mimicking POEMS syndrome
inferred← citeshttps://doi.org/10.1111/all.14254openalex-snapshot
Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI‐mediated signaling
inferred← citeshttps://doi.org/10.1111/bjh.19501openalex-snapshot
Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation
inferred← citeshttps://doi.org/10.1111/eci.12607openalex-snapshot
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis
inferred← citeshttps://doi.org/10.1111/ejh.12537openalex-snapshot
Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis
inferred← citeshttps://doi.org/10.1111/ejh.70004openalex-snapshot
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges
inferred← citeshttps://doi.org/10.1111/imm.13571openalex-snapshot
Epigenetics: An opportunity to shape innate and adaptive immune responses
inferred← citeshttps://doi.org/10.1111/imr.12236openalex-snapshot
Role of the ubiquitin proteasome system in hematologic malignancies
inferred← citeshttps://doi.org/10.1111/joim.12410openalex-snapshot
Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease
inferred← citeshttps://doi.org/10.1146/annurev-pathmechdis-031521-042618openalex-snapshot
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
inferred← citeshttps://doi.org/10.1155/2018/6928571openalex-snapshot
Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia
inferred← citeshttps://doi.org/10.1155/crom/3563591openalex-snapshot
KIT‐Negative Systemic Mastocytosis Associated With Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1158/0008-5472.can-16-2234openalex-snapshot
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
inferred← citeshttps://doi.org/10.1159/000504099openalex-snapshot
The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review
inferred← citeshttps://doi.org/10.1172/jci.insight.94679openalex-snapshot
Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway
inferred← citeshttps://doi.org/10.1172/jci67509openalex-snapshot
Pak and Rac GTPases promote oncogenic KIT–induced neoplasms
inferred← citeshttps://doi.org/10.1182/asheducation-2015.1.98openalex-snapshot
Diagnosis and management of mastocytosis: an emerging challenge in applied hematology
inferred← citeshttps://doi.org/10.1182/blood-2013-04-496448openalex-snapshot
Comprehensive mutational profiling in advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.1182/blood-2013-06-460295openalex-snapshot
The biology and clinical impact of genetic lesions in myeloid malignancies
inferred← citeshttps://doi.org/10.1182/blood-2014-08-594564openalex-snapshot
Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation
inferred← citeshttps://doi.org/10.1182/blood-2016-09-731893openalex-snapshot
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
inferred← citeshttps://doi.org/10.1182/blood.2018886507openalex-snapshot
Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis
inferred← citeshttps://doi.org/10.1182/blood.2019000932openalex-snapshot
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.1182/bloodadvances.2018020628openalex-snapshot
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
inferred← citeshttps://doi.org/10.1182/bloodadvances.2022007539openalex-snapshot
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.1182/bloodadvances.2023012006openalex-snapshot
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
inferred← citeshttps://doi.org/10.1186/s12920-021-01145-0openalex-snapshot
Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel
inferred← citeshttps://doi.org/10.12688/f1000research.12384.1openalex-snapshot
Epigenetic and transcriptional control of mast cell responses
inferred← citeshttps://doi.org/10.1371/journal.pone.0076241openalex-snapshot
Familial Occurrence of Systemic Mast Cell Activation Disease
inferred← citeshttps://doi.org/10.1371/journal.pone.0085362openalex-snapshot
ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
inferred← citeshttps://doi.org/10.1371/journal.pone.0096209openalex-snapshot
Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis
inferred← citeshttps://doi.org/10.1371/journal.pone.0099769openalex-snapshot
Rapid Detection of DNMT3A R882 Mutations in Hematologic Malignancies Using a Novel Bead-Based Suspension Assay with BNA(NC) Probes
inferred← citeshttps://doi.org/10.1371/journal.pone.0142450openalex-snapshot
Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
inferred← citeshttps://doi.org/10.14348/molcells.2015.0294openalex-snapshot
Functions of TET Proteins in Hematopoietic Transformation
inferred← citeshttps://doi.org/10.18632/oncotarget.10861openalex-snapshot
c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus
inferred← citeshttps://doi.org/10.18632/oncotarget.23354openalex-snapshot
Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia
inferred← citeshttps://doi.org/10.18632/oncotarget.4213openalex-snapshot
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
inferred← citeshttps://doi.org/10.20452/pamw.15212openalex-snapshot
How to diagnose Mast Cell Activation Syndrome? Practical considerations
inferred← citeshttps://doi.org/10.21203/rs.3.rs-721996/v1openalex-snapshot
Analysis of Genetic Variants in Myeloproliferative Neoplasms Using a 22-Gene Next-Generation Sequencing Panel
inferred← citeshttps://doi.org/10.3324/haematol.2013.090506openalex-snapshot
SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype
inferred← citeshttps://doi.org/10.3324/haematol.2016.146563openalex-snapshot
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice
inferred← citeshttps://doi.org/10.3324/haematol.2018.195867openalex-snapshot
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
inferred← citeshttps://doi.org/10.3389/fmed.2017.00110openalex-snapshot
Targeted Treatment Options in Mastocytosis
inferred← citeshttps://doi.org/10.3390/cancers14102487openalex-snapshot
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis
inferred← citeshttps://doi.org/10.3390/cancers14133070openalex-snapshot
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells
inferred← citeshttps://doi.org/10.3390/cancers16152634openalex-snapshot
Decoding Clonal Hematopoiesis: Emerging Themes and Novel Mechanistic Insights
inferred← citeshttps://doi.org/10.3390/cells8050437openalex-snapshot
The Role of Mast Cells in Stroke
inferred← citeshttps://doi.org/10.3390/ijms20122976openalex-snapshot
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
inferred← citeshttps://doi.org/10.3390/ijms21155506openalex-snapshot
Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups
inferred← citeshttps://doi.org/10.3390/ijms22062964openalex-snapshot
Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
inferred← citeshttps://doi.org/10.3390/ijms222011270openalex-snapshot
Mastocytosis and Mast Cell Activation Disorders: Clearing the Air
inferred← citeshttps://doi.org/10.3390/ijms252010885openalex-snapshot
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why
inferred← citeshttps://doi.org/10.3390/molecules24122297openalex-snapshot
Bridged Nucleic Acids Reloaded
inferred← citeshttps://doi.org/10.3410/f.727367719.793539110openalex-snapshot
Faculty Opinions recommendation of Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.
inferred← citeshttps://doi.org/10.3410/f.733590638.793566952openalex-snapshot
Faculty Opinions recommendation of Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
inferred← citeshttps://doi.org/10.4084/mjhid.2021.046openalex-snapshot
SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT
inferred← citeshttps://doi.org/10.4103/ijpm.ijpm_824_18openalex-snapshot
Loss of c-Cbl expression correlates with de-differentiation status and lymphatic metastasis in gastric cancer
inferred← citeshttps://doi.org/10.6004/jnccn.2018.0088openalex-snapshot
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
inferred← citeshttps://doi.org/10.70675/52e86990z6280z43a5zbab1z4fb14a321c87openalex-snapshot
Neoplastic mast cells from patients with mastocytosis express AXL : effects on proliferation, apoptosis, and resistance to tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.7912/c2/1961openalex-snapshot
Mechanism of Transformation and Therapeutic Targets for Hematological Neoplasms Harboring Oncogenic KIT Mutation
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.